Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Norvir Capsule Production Problem Leaves Liquid As Only Formulation

Executive Summary

Abbott's protease inhibitor Norvir (ritonavir) soon will be available only in liquid form as the company works to correct a manufacturing problem resulting in improper dissolution of the capsule form, the company said in a letter to doctors, pharmacists and patients.

You may also be interested in...



Abbott Norvir Returns To Market Via Contract Manufacturer

Abbott's HIV protease inhibitor Norvir capsules will be available the week of July 5 as a soft gelatin reformulation outsourced to a contract manufacturer.

Abbott Norvir Returns To Market Via Contract Manufacturer

Abbott's HIV protease inhibitor Norvir capsules will be available the week of July 5 as a soft gelatin reformulation outsourced to a contract manufacturer.

Norvir

Abbott files NDA for soft-gel capsule formulation of the protease inhibitor ritonavir. Manufacture of the original capsules was stopped because a new crystalline structure encountered during production affected the product's dissolution (1"The Pink Sheet" Aug. 3, 1998, p. 21). The product "was reformulated to accommodate a new and stable crystalline structure of ritonavir." Oral solution continues to be available in the interim

Latest Headlines
See All
UsernamePublicRestriction

Register

PS032574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel